Literature DB >> 21720250

Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus.

Richard G Moore1, Craig Michael Miller, Amy K Brown, Katina Robison, Margaret Steinhoff, Geralyn Lambert-Messerlian.   

Abstract

OBJECTIVE: The purpose of this pilot study was to determine whether the biomarker human epididymis protein 4 (HE4) correlates with depth of myometrial invasion, histologic grade, lymph vascular space invasion, positive cytologic washings, and nodal metastases in patients with endometrioid adenocarcinoma of the uterus.
METHODS: This was a prospective, observational study in women with biopsy-proven endometrioid adenocarcinoma. Concentrations of HE4 were assessed before surgery, and all surgical specimens were reviewed by dedicated gynecologic pathologists.
RESULTS: Included were a total of 96 women with endometrioid adenocarcinomas of the uterus, most (77%) with stage I disease. Levels of serum HE4 greater than 70 pM displayed a sensitivity of 94% and a negative predictive value of 97% in identifying stage IA (<50% myometrial invasion) versus stage IB (≥ 50% myometrial invasion) tumors and a sensitivity of 82% and negative predictive value of 82% versus all more advanced tumors.
CONCLUSIONS: Human epididymis protein 4 may be a useful marker preoperatively in the clinical decision process for determining the need for lymph node dissection in women with endometrioid endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720250     DOI: 10.1097/IGC.0b013e3182229ad8

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  21 in total

1.  The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.

Authors:  Roberto Angioli; Stella Capriglione; Giuseppe Scaletta; Alessia Aloisi; Andrea Miranda; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2015-11-03

2.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

Review 3.  Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.

Authors:  Stella Capriglione; Daniela Luvero; Francesco Plotti; Corrado Terranova; Roberto Montera; Giuseppe Scaletta; Teresa Schirò; Gianmarco Rossini; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2017-08-20       Impact factor: 3.064

Review 4.  The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Authors:  Archana R Simmons; Keith Baggerly; Robert C Bast
Journal:  Oncology (Williston Park)       Date:  2013-06       Impact factor: 2.990

5.  The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Elisa Paviati; Silvia Giudici; Orazio Ruzzenente; Massimo Franchi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

6.  Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset.

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Giuseppe Scaletta; Salvatore Lopez; Daniela Luvero; Antonelli Gianina; Alessia Aloisi; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2017-04-07       Impact factor: 3.064

7.  Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.

Authors:  Stella Capriglione; Francesco Plotti; Andrea Miranda; Roberto Ricciardi; Giuseppe Scaletta; Alessia Aloisi; Federica Guzzo; Roberto Montera; Roberto Angioli
Journal:  Tumour Biol       Date:  2015-01-11

Review 8.  A critical review on HE4 performance in endometrial cancer: where are we now?

Authors:  Roberto Angioli; Andrea Miranda; Alessia Aloisi; Roberto Montera; Stella Capriglione; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2013-09-26

9.  Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study.

Authors:  Rupali Dewan; Abhinav Dewan; Swati Hare; Mausumi Bhardwaj; Krati Mehrotra
Journal:  J Clin Diagn Res       Date:  2017-07-01

10.  The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.

Authors:  Roberto Angioli; Francesco Plotti; Stella Capriglione; Roberto Montera; Patrizio Damiani; Roberto Ricciardi; Alessia Aloisi; Daniela Luvero; Ester Valentina Cafà; Nella Dugo; Michela Angelucci; Pierluigi Benedetti-Panici
Journal:  Tumour Biol       Date:  2012-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.